Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

Advances in the science and treatment of alcohol use disorder.

Witkiewitz K, Litten RZ, Leggio L.

Sci Adv. 2019 Sep 25;5(9):eaax4043. doi: 10.1126/sciadv.aax4043. eCollection 2019 Sep. Review.

2.

Maintenance of World Health Organization Risk Drinking Level Reductions and Posttreatment Functioning Following a Large Alcohol Use Disorder Clinical Trial.

Witkiewitz K, Falk DE, Litten RZ, Hasin DS, Kranzler HR, Mann KF, O'Malley SS, Anton RF.

Alcohol Clin Exp Res. 2019 May;43(5):979-987. doi: 10.1111/acer.14018. Epub 2019 Apr 5.

3.

Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials.

Falk DE, O'Malley SS, Witkiewitz K, Anton RF, Litten RZ, Slater M, Kranzler HR, Mann KF, Hasin DS, Johnson B, Meulien D, Ryan M, Fertig J; Alcohol Clinical Trials Initiative (ACTIVE) Workgroup.

JAMA Psychiatry. 2019 Apr 1;76(4):374-381. doi: 10.1001/jamapsychiatry.2018.3079.

PMID:
30865232
4.

Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial Assessing Efficacy and Safety.

Falk DE, Ryan ML, Fertig JB, Devine EG, Cruz R, Brown ES, Burns H, Salloum IM, Newport DJ, Mendelson J, Galloway G, Kampman K, Brooks C, Green AI, Brunette MF, Rosenthal RN, Dunn KE, Strain EC, Ray L, Shoptaw S, Ait-Daoud Tiouririne N, Gunderson EW, Ransom J, Scott C, Leggio L, Caras S, Mason BJ, Litten RZ; National Institute on Alcohol Abuse and Alcoholism Clinical Investigations Group (NCIG) Study Group.

Alcohol Clin Exp Res. 2019 Jan;43(1):158-169. doi: 10.1111/acer.13917. Epub 2018 Dec 9.

PMID:
30403402
5.

Drinking Risk Level Reductions Associated with Improvements in Physical Health and Quality of Life Among Individuals with Alcohol Use Disorder.

Witkiewitz K, Kranzler HR, Hallgren KA, O'Malley SS, Falk DE, Litten RZ, Hasin DS, Mann KF, Anton RF.

Alcohol Clin Exp Res. 2018 Dec;42(12):2453-2465. doi: 10.1111/acer.13897. Epub 2018 Nov 5.

PMID:
30395350
6.

Advances in Pharmacotherapy Development: Human Clinical Studies.

Litten RZ, Falk DE, Ryan ML, Fertig J, Leggio L.

Handb Exp Pharmacol. 2018;248:579-613. doi: 10.1007/164_2017_79. Review.

PMID:
29294197
7.

Letter to Editor in Response to Johnson's Commentary (2017) on the Witkiewitz and Colleagues (2017) Article.

Litten RZ, Falk DE, O'Malley SS, Witkiewitz KA, Mann KF, Anton RF.

Alcohol Clin Exp Res. 2017 Jul;41(7):1381-1382. doi: 10.1111/acer.13411. Epub 2017 May 23. No abstract available.

8.

Temporal Stability of Heavy Drinking Days and Drinking Reductions Among Heavy Drinkers in the COMBINE Study.

Witkiewitz K, Wilson AD, Pearson MR, Hallgren KA, Falk DE, Litten RZ, Kranzler HR, Mann KF, Hasin DS, O'Malley SS, Anton RF.

Alcohol Clin Exp Res. 2017 May;41(5):1054-1062. doi: 10.1111/acer.13371. Epub 2017 Apr 5.

9.

Addictions Neuroclinical Assessment: A reverse translational approach.

Kwako LE, Momenan R, Grodin EN, Litten RZ, Koob GF, Goldman D.

Neuropharmacology. 2017 Aug 1;122:254-264. doi: 10.1016/j.neuropharm.2017.03.006. Epub 2017 Mar 7. Review.

10.

Posttreatment Low-Risk Drinking as a Predictor of Future Drinking and Problem Outcomes Among Individuals with Alcohol Use Disorders: A 9-Year Follow-Up.

Kline-Simon AH, Litten RZ, Weisner CM, Falk DE.

Alcohol Clin Exp Res. 2017 Mar;41(3):653-658. doi: 10.1111/acer.13334. Epub 2017 Feb 7.

11.

Clinical Validation of Reduced Alcohol Consumption After Treatment for Alcohol Dependence Using the World Health Organization Risk Drinking Levels.

Witkiewitz K, Hallgren KA, Kranzler HR, Mann KF, Hasin DS, Falk DE, Litten RZ, O'Malley SS, Anton RF.

Alcohol Clin Exp Res. 2017 Jan;41(1):179-186. doi: 10.1111/acer.13272. Epub 2016 Dec 26.

12.

Reply to: Neuroclinical Assessment of Addiction Needs to Incorporate Decision-Making Measures and Ecological Validity.

Kwako LE, Momenan R, Litten RZ, Koob GF, Goldman D.

Biol Psychiatry. 2017 Apr 1;81(7):e55. doi: 10.1016/j.biopsych.2016.08.029. Epub 2016 Aug 30. No abstract available.

PMID:
27776735
13.

Nociceptin Receptor as a Target to Treat Alcohol Use Disorder: Challenges in Advancing Medications Development.

Litten RZ.

Alcohol Clin Exp Res. 2016 Nov;40(11):2299-2304. doi: 10.1111/acer.13222. Epub 2016 Oct 3. No abstract available.

PMID:
27696442
14.

A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence.

Ryan ML, Falk DE, Fertig JB, Rendenbach-Mueller B, Katz DA, Tracy KA, Strain EC, Dunn KE, Kampman K, Mahoney E, Ciraulo DA, Sickles-Colaneri L, Ait-Daoud N, Johnson BA, Ransom J, Scott C, Koob GF, Litten RZ.

Neuropsychopharmacology. 2017 Apr;42(5):1012-1023. doi: 10.1038/npp.2016.214. Epub 2016 Sep 23.

15.

An exploratory evaluation of Take Control: A novel computer-delivered behavioral platform for placebo-controlled pharmacotherapy trials for alcohol use disorder.

Devine EG, Ryan ML, Falk DE, Fertig JB, Litten RZ.

Contemp Clin Trials. 2016 Sep;50:178-85. doi: 10.1016/j.cct.2016.08.006. Epub 2016 Aug 10.

16.

Missing Data in Alcohol Clinical Trials with Binary Outcomes.

Hallgren KA, Witkiewitz K, Kranzler HR, Falk DE, Litten RZ, O'Malley SS, Anton RF; In conjunction with the Alcohol Clinical Trials Initiative (ACTIVE) Workgroup.

Alcohol Clin Exp Res. 2016 Jul;40(7):1548-57. doi: 10.1111/acer.13106. Epub 2016 Jun 2.

17.

Discovery, Development, and Adoption of Medications to Treat Alcohol Use Disorder: Goals for the Phases of Medications Development.

Litten RZ, Falk DE, Ryan ML, Fertig JB.

Alcohol Clin Exp Res. 2016 Jul;40(7):1368-79. doi: 10.1111/acer.13093. Epub 2016 May 17. Review.

18.

Potential medications for the treatment of alcohol use disorder: An evaluation of clinical efficacy and safety.

Litten RZ, Wilford BB, Falk DE, Ryan ML, Fertig JB.

Subst Abus. 2016 Apr-Jun;37(2):286-98. doi: 10.1080/08897077.2015.1133472. Review.

PMID:
26928397
19.

Addictions Neuroclinical Assessment: A Neuroscience-Based Framework for Addictive Disorders.

Kwako LE, Momenan R, Litten RZ, Koob GF, Goldman D.

Biol Psychiatry. 2016 Aug 1;80(3):179-89. doi: 10.1016/j.biopsych.2015.10.024. Epub 2015 Nov 17. Review.

20.

Measures of outcome for stimulant trials: ACTTION recommendations and research agenda.

Kiluk BD, Carroll KM, Duhig A, Falk DE, Kampman K, Lai S, Litten RZ, McCann DJ, Montoya ID, Preston KL, Skolnick P, Weisner C, Woody G, Chandler R, Detke MJ, Dunn K, Dworkin RH, Fertig J, Gewandter J, Moeller FG, Ramey T, Ryan M, Silverman K, Strain EC.

Drug Alcohol Depend. 2016 Jan 1;158:1-7. doi: 10.1016/j.drugalcdep.2015.11.004. Epub 2015 Nov 21. Review.

21.

Moderators of Varenicline Treatment Effects in a Double-Blind, Placebo-Controlled Trial for Alcohol Dependence: An Exploratory Analysis.

Falk DE, Castle IJ, Ryan M, Fertig J, Litten RZ.

J Addict Med. 2015 Jul-Aug;9(4):296-303. doi: 10.1097/ADM.0000000000000133.

22.

Heterogeneity of alcohol use disorder: understanding mechanisms to advance personalized treatment.

Litten RZ, Ryan ML, Falk DE, Reilly M, Fertig JB, Koob GF.

Alcohol Clin Exp Res. 2015 Apr;39(4):579-84. doi: 10.1111/acer.12669. No abstract available.

PMID:
25833016
23.

Methods to analyze treatment effects in the presence of missing data for a continuous heavy drinking outcome measure when participants drop out from treatment in alcohol clinical trials.

Witkiewitz K, Falk DE, Kranzler HR, Litten RZ, Hallgren KA, O'Malley SS, Anton RF; Alcohol Clinical Trials Initiative (ACTIVE) Workgroup.

Alcohol Clin Exp Res. 2014 Nov;38(11):2826-34. doi: 10.1111/acer.12543.

24.

Alcohol medications development: advantages and caveats of government/academia collaborating with the pharmaceutical industry.

Litten RZ, Ryan M, Falk D, Fertig J.

Alcohol Clin Exp Res. 2014 May;38(5):1196-9. doi: 10.1111/acer.12357. Epub 2014 Apr 1.

PMID:
24689461
25.

Cumulative proportion of responders analysis (CPRA) as a tool to assess treatment outcome in alcohol clinical trials.

Falk DE, Litten RZ, Anton RF, Kranzler HR, Johnson BA; Active Workgroup.

J Stud Alcohol Drugs. 2014 Mar;75(2):335-46.

26.

Risks of alcohol use disorders related to drinking patterns in the U.S. general population.

Greenfield TK, Ye Y, Bond J, Kerr WC, Nayak MB, Kaskutas LA, Anton RF, Litten RZ, Kranzler HR.

J Stud Alcohol Drugs. 2014 Mar;75(2):319-27.

27.

Five-year healthcare utilization and costs among lower-risk drinkers following alcohol treatment.

Kline-Simon AH, Weisner CM, Parthasarathy S, Falk DE, Litten RZ, Mertens JR.

Alcohol Clin Exp Res. 2014 Feb;38(2):579-86. doi: 10.1111/acer.12273. Epub 2013 Oct 7.

28.

The placebo effect in clinical trials for alcohol dependence: an exploratory analysis of 51 naltrexone and acamprosate studies.

Litten RZ, Castle IJ, Falk D, Ryan M, Fertig J, Chen CM, Yi HY.

Alcohol Clin Exp Res. 2013 Dec;37(12):2128-37. doi: 10.1111/acer.12197. Epub 2013 Jul 24.

29.

Research opportunities for medications to treat alcohol dependence: addressing stakeholders' needs.

Litten RZ, Falk D, Ryan M, Fertig J.

Alcohol Clin Exp Res. 2014 Jan;38(1):27-32. doi: 10.1111/acer.12193. Epub 2013 Jul 24. Review.

PMID:
23889161
30.

A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence.

Litten RZ, Ryan ML, Fertig JB, Falk DE, Johnson B, Dunn KE, Green AI, Pettinati HM, Ciraulo DA, Sarid-Segal O, Kampman K, Brunette MF, Strain EC, Tiouririne NA, Ransom J, Scott C, Stout R; NCIG (National Institute on Alcohol Abuse and Alcoholism Clinical Investigations Group) Study Group.

J Addict Med. 2013 Jul-Aug;7(4):277-86. doi: 10.1097/ADM.0b013e31829623f4.

31.

Assessing the drinking status of liver transplant patients with alcoholic liver disease.

Allen JP, Wurst FM, Thon N, Litten RZ.

Liver Transpl. 2013 Apr;19(4):369-76. doi: 10.1002/lt.23596. Epub 2013 Mar 17. Review.

32.

Posttreatment low-risk drinking as a predictor of future drinking and problem outcomes among individuals with alcohol use disorders.

Kline-Simon AH, Falk DE, Litten RZ, Mertens JR, Fertig J, Ryan M, Weisner CM.

Alcohol Clin Exp Res. 2013 Jan;37 Suppl 1:E373-80. doi: 10.1111/j.1530-0277.2012.01908.x. Epub 2012 Jul 24.

33.

Medications development to treat alcohol dependence: a vision for the next decade.

Litten RZ, Egli M, Heilig M, Cui C, Fertig JB, Ryan ML, Falk DE, Moss H, Huebner R, Noronha A.

Addict Biol. 2012 May;17(3):513-27. doi: 10.1111/j.1369-1600.2012.00454.x. Epub 2012 Mar 28. Review.

34.

A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients.

Fertig JB, Ryan ML, Falk DE, Litten RZ, Mattson ME, Ransom J, Rickman WJ, Scott C, Ciraulo D, Green AI, Tiouririne NA, Johnson B, Pettinati H, Strain EC, Devine E, Brunette MF, Kampman K, A Tompkins D, Stout R; NCIG 002 Study Group.

Alcohol Clin Exp Res. 2012 Aug;36(8):1421-30. doi: 10.1111/j.1530-0277.2011.01716.x. Epub 2012 Feb 10.

35.

A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients.

Litten RZ, Fertig JB, Falk DE, Ryan ML, Mattson ME, Collins JF, Murtaugh C, Ciraulo D, Green AI, Johnson B, Pettinati H, Swift R, Afshar M, Brunette MF, Tiouririne NA, Kampman K, Stout R; NCIG 001 Study Group.

Alcohol Clin Exp Res. 2012 Mar;36(3):406-16. doi: 10.1111/j.1530-0277.2011.01649.x. Epub 2011 Sep 26.

36.

The Alcohol Clinical Trials Initiative (ACTIVE): purpose and goals for assessing important and salient issues for medications development in alcohol use disorders.

Anton RF, Litten RZ, Falk DE, Palumbo JM, Bartus RT, Robinson RL, Kranzler HR, Kosten TR, Meyer RE, O'Brien CP, Mann K, Meulien D.

Neuropsychopharmacology. 2012 Jan;37(2):402-11. doi: 10.1038/npp.2011.182. Epub 2011 Sep 7.

37.

Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials.

Falk D, Wang XQ, Liu L, Fertig J, Mattson M, Ryan M, Johnson B, Stout R, Litten RZ.

Alcohol Clin Exp Res. 2010 Dec;34(12):2022-34. doi: 10.1111/j.1530-0277.2010.01290.x.

PMID:
20659066
38.

Alcohol biomarkers in applied settings: recent advances and future research opportunities.

Litten RZ, Bradley AM, Moss HB.

Alcohol Clin Exp Res. 2010 Jun;34(6):955-67. doi: 10.1111/j.1530-0277.2010.01170.x. Epub 2010 Apr 5.

PMID:
20374219
39.

Combining treatments for alcoholism: why and how?

Mattson ME, Litten RZ.

J Stud Alcohol Suppl. 2005 Jul;(15):8-16; discussion 6-7. Review.

PMID:
16223051
40.

Challenges and opportunities for medications development in alcoholism: an international perspective on collaborations between academia and industry.

Johnson BA, Mann K, Willenbring ML, Litten RZ, Swift RM, Lesch OM, Berglund M.

Alcohol Clin Exp Res. 2005 Aug;29(8):1528-40.

PMID:
16156050
41.

Development of medications for alcohol use disorders: recent advances and ongoing challenges.

Litten RZ, Fertig J, Mattson M, Egli M.

Expert Opin Emerg Drugs. 2005 May;10(2):323-43. Review.

PMID:
15934870
42.

Co-occurring alcohol and cocaine dependence: recent findings from clinical and field studies.

Flanner BA, Morgenstern J, McKay J, Wechsberg WM, Litten RZ.

Alcohol Clin Exp Res. 2004 Jun;28(6):976-81.

PMID:
15218883
43.

Pharmacological treatment of alcohol abuse/dependence with psychiatric comorbidity.

Le Fauve CE, Litten RZ, Randall CL, Moak DH, Salloum IM, Green AI.

Alcohol Clin Exp Res. 2004 Feb;28(2):302-12.

PMID:
15112938
44.

Self-report and biochemical measures of alcohol consumption.

Litten RZ, Fertig J.

Addiction. 2003 Dec;98 Suppl 2:iii-iv. Review. No abstract available.

PMID:
14984236
45.

Recommendations on use of biomarkers in alcoholism treatment trials.

Allen JP, Litten RZ.

Alcohol Clin Exp Res. 2003 Oct;27(10):1667-70.

PMID:
14574239
46.

Introduction: National Institute on Alcohol Abuse and Alcoholism workshop on treatment research priorities and health disparities.

Le Fauve CE, Lowman C, Litten RZ 3rd, Mattson ME.

Alcohol Clin Exp Res. 2003 Aug;27(8):1318-20. Review. No abstract available.

PMID:
12966328
47.

Using acquired knowledge and new technologies in alcoholism treatment trials.

Flannery BA, Allen JP, Pettinati HM, Rohsenow DJ, Cisler RA, Litten RZ.

Alcohol Clin Exp Res. 2002 Mar;26(3):423-9.

PMID:
11923598
48.

The role of biomarkers in alcoholism medication trials.

Allen JP, Litten RZ, Strid N, Sillanaukee P.

Alcohol Clin Exp Res. 2001 Aug;25(8):1119-25. Review.

PMID:
11505042
49.

Carbohydrate-deficient transferrin: an aid to early recognition of alcohol relapse.

Allen JP, Litten RZ, Fertig JB, Sillanaukee P.

Am J Addict. 2001;10(s1):s24-s28. Review.

PMID:
11268818
50.

The role of laboratory tests in alcoholism treatment.

Allen JP, Litten RZ.

J Subst Abuse Treat. 2001 Jan;20(1):81-5. Review.

PMID:
11239731

Supplemental Content

Loading ...
Support Center